Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...

Targeting T cells with ustekinumab is a potential therapeutic strategy for AAV-GN that merits additional evaluation in ...

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's ...

On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.